TARS vs TT · rev $183.0M vs P/E 36, rev $21.32B
Tarsus Pharmaceuticals Inc (TARS) versus Trane Technologies plc (TT) — a side-by-side from cached financials, not a winner call.
Tarsus Pharmaceuticals Inc (TARS) is a biotechnology company listed on NASDAQ.
Trane Technologies plc (TT) is a building products & equipment company listed on NYSE.
Latest reported TARS revenue for 2024-12-31 was $183.0M. Net income was -$115.6M. Revenue was up 948.6% from 2023-12-31 to 2024-12-31. TARS currently screens at market cap $2.66B.
Latest reported TT revenue for 2025-12-31 was $21.32B. Net income was $2.92B. Revenue was up 7.5% from 2024-12-31 to 2025-12-31. TT currently screens at market cap $104.45B and trailing P/E 36.2.
TARS currently screens at market cap $2.66B. TT currently screens at market cap $104.45B and trailing P/E 36.2.
Not investment advice. Open the TARS and TT stock pages for the full models.
Not investment advice.